Nootropics Index - Save on smarter supplements
Nootropics>Peptides, proteins & enzymes>BPC-157
Peptides, proteins & enzymes

BPC-157

BPC-157 / Bepecin peptide

BPC-157 (Bepecin) is an investigational synthetic 15-amino-acid peptide. Human evidence now includes older enema abstracts, a retrospective knee-pain series, a 12-person bladder pilot, and a two-person intravenous safety pilot, but none establishes a consumer recovery benefit or a safe oral or subcutaneous protocol. FDA's May 2026 evaluation found insufficient clinical safety information and proposed that BPC-157 free base and acetate not be added to the U.S. 503A Bulks List; the July 23 advisory meeting and final determination were still pending as of July 14, 2026. WADA's 2026 list prohibits BPC-157 at all times for WADA-governed sport.

SyntheticMostly Animal EvidenceEmerging ResearchInsufficient EvidenceForm Dependent EvidenceHigh Risk ProfilePregnancy Caution
Updated July 2026/7 min read/12 citations
Prepared by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

Bepecin is BPC-157

1

The active listings under Bepecin are BPC-157 products. BPC-157 is a synthetic 15-amino-acid peptide also called body protective compound 15, PL-14736, PL-10, or PLD-116.

Not a routine nootropic or supplement4
BPC-157 is an investigational peptide, not a routine nootropic. Very small human reports exist, but they do not validate consumer recovery, cognition, or self-injection claims. It is WADA-prohibited for governed sport.

Human evidence is preliminary and route-specific

3

Published human reports include a retrospective knee series, an uncontrolled 12-person bladder pilot, and a two-person intravenous safety pilot. Older enema evidence is largely available as meeting abstracts. These reports do not establish oral or subcutaneous recovery efficacy.

02

Names, aliases and forms

Common NamesBPC-157; Bepecin
Chemical NameBody protective compound 15
Research CodesPL 14736; PL10; PLD-116
Peptide SequencesGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; GEPPPGKPADDAGLV
Salt FormBPC-157 acetate
Regulatory NameUNII 8ED8NXK95P
03

Mechanisms of action

Repair biology is mostly preclinical

3

Animal and cell literature discusses wound healing, gastrointestinal protection, nitric-oxide pathways, angiogenesis, tendon and ligament repair, and vascular responses. FDA notes that molecular targets remain unidentified and dose-response relationships are not established, limiting translation to people.

04

Potential effects and evidence map

Most recovery claims remain animal or mechanistic. Published human evidence is limited to small uncontrolled or retrospective route-specific reports plus older enema abstracts; none confirms oral or subcutaneous recovery efficacy. A 120-participant Phase 2 hamstring trial began recruiting in 2026 but has no results. FDA's May 2026 evaluation found insufficient clinical safety data, no human pharmacokinetic data for oral, subcutaneous, nasal, or transdermal routes, and concerns about identity, impurities, aggregation, and immunogenicity. This supports a Grade D, high-risk investigational framing: not animal-only, but far from validated.

Effect domainMagnitudeGrade
Physical energy / endurance5
UnknownConfidence: Low

Animal studies and a small retrospective knee series suggest a weak musculoskeletal-repair signal, but no controlled human evidence shows faster recovery or improved performance.

Note The taxonomy lacks a repair or pain domain. The knee report was retrospective and uncontrolled, while the recruiting Phase 2 hamstring trial has no results.

1/5
D
Cellular / long-term brain support6
UnknownConfidence: Medium

No reliable human evidence supports nootropic, neuroprotective, focus, memory, or mood benefits.

Note Human reports concern knee pain, bladder symptoms, short route-specific exposure, or safety?not healthy-user cognition.

0/5
E
05

Typical dosages and timing

Capsule listing120.5 mg/capsule

One indexed retailer lists 0.5 mg per capsule. This is product-strength and price-normalization context only?not a validated dose, protocol, or evidence of lawful marketing.

Common vial size5 mg/vial

Some indexed products are sold as 5 mg vials or acetate aliquots. Vial content is not a dose; reconstitution, route, identity, sterility, concentration, and administration determine exposure and risk.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
A controlled trial is recruiting7

NCT07437547 is recruiting 120 participants for staff-administered subcutaneous BPC-157 or placebo once daily for 14 days after acute hamstring strain. Results are not expected before the planned completion period and registry timing is not a consumer protocol.

07

Safety, side effects and risk profile

Concurrent care and procedures3
Human combination data are unavailable. People receiving prescription treatment, active cancer care, or preparing for surgery should not self-administer an investigational peptide outside regulated research or specialist care.
Legal / regulatory risk4
Confidence: High

BPC-157 is prohibited at all times for WADA-governed sport; the U.S. compounding review is adverse but not final.

Note WADA 2026 names BPC-157 under S0. FDA proposes excluding free base and acetate from the U.S. 503A Bulks List, with advisory review scheduled for July 23, 2026.

5/5
A
Evidence uncertainty3
Confidence: High

Clinical safety and efficacy remain too limited to define safe consumer use across common routes.

Note FDA found insufficient clinical safety information and no human pharmacokinetic data for oral, subcutaneous, nasal, or transdermal administration.

5/5
A
Pregnancy / lactation caution3
Confidence: High

Pregnancy, lactation, and pediatric safety have not been established.

Note Avoid self-administration in these groups outside regulated research or specialist care.

4/5
E
Headache / dizziness3
Confidence: Low

Headache appeared in older enema-study abstracts without a clear difference from placebo.

Note Route relevance is uncertain; this does not establish a common adverse effect for capsules or injections.

1/5
D
GI discomfort3
Confidence: Low

Flatulence appeared in older enema-study abstracts without a clear difference from placebo.

Note The finding is route-specific and does not establish general oral or injectable tolerability.

1/5
D
FDA peptide-compounding concerns3

FDA reports insufficient clinical safety information, unresolved identity and quality attributes, and potential aggregation, impurity, and immunogenicity concerns?especially for injectable and nasal formulations.

Self-injection and gray-market risk3

Self-injection adds risks that capsules do not: sterility and endotoxin failures, reconstitution and dosing error, needle injury, local infection, immune reaction, mislabeled concentration, counterfeit material, and poorly characterized peptide combinations.

What the limited human safety record shows3

FDA found no serious adverse events in several very small, short reports, but monitoring was limited. Three FAERS reports involved injection-site redness and swelling, shortness of breath, or pigmentation changes; causality was unclear because of sparse details or concurrent products.

08

Legal and regulatory status

WADA prohibited at all times4

The 2026 WADA Prohibited List names BPC-157 under S0 non-approved substances. This category is prohibited at all times, both in competition and out of competition.

U.S. compounding review is adverse but not final3

FDA currently lists BPC-157 among substances that may present significant compounding safety risks. Its May 2026 evaluation proposes that BPC-157 free base and acetate not be added to the 503A Bulks List, but the July 23 advisory meeting and final agency determination were still pending as of July 14, 2026.

09

Practical buying and quality notes

  • Verify the full GEPPPGKPADDAGLV sequence, free base versus acetate identity, net peptide amount, route, HPLC/MS identity, impurity and aggregation controls, storage, and?where sterility is claimed?validated sterility and endotoxin testing. A generic purity percentage or COA is not enough.3
  • A low price per vial can hide identity, concentration, aggregation, sterility, or counterfeit risk. For WADA-governed athletes, product testing does not change the S0 prohibition.4
10

FAQ

What is Bepecin?

1

Bepecin is a synonym for BPC-157, a synthetic pentadecapeptide also called body protective compound 15, PL-14736, PL-10, or PLD-116.

What is the BPC-157 dosage?

12

There is no validated consumer dose. Indexed products include 0.5 mg capsules and 5 mg vials, but those are retail strengths?not approved dosing, cycling, or reconstitution guidance.

How long does BPC-157 take to work?

3

Human onset and effect duration are not established, and FDA found no human pharmacokinetic data for common oral, subcutaneous, nasal, or transdermal routes. Animal timelines and online cycles are not evidence-based human schedules.

Is BPC-157 proven for injury recovery?

5

No. A retrospective knee series and other small uncontrolled route-specific reports are hypothesis-generating, while the recruiting Phase 2 hamstring trial has no results. Controlled human evidence does not yet validate faster injury recovery.

Is BPC-157 allowed for athletes?

4

No for WADA-governed sport. The 2026 WADA list names BPC-157 under S0 non-approved substances, prohibited at all times in and out of competition.

11

References

  1. NCATS Inxight Drugs. BPC-157 (UNII 8ED8NXK95P). Accessed 2026-07-14.
  2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 2026-07-14.
  3. U.S. Food and Drug Administration. Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 Free Base and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List. FDA briefing document dated May 11, 2026.
  4. World Anti-Doping Agency. International Standard: Prohibited List 2026. In force January 1, 2026.
  5. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):15563316251355551.
  6. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619.
  7. ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR), NCT07437547. Accessed 2026-07-14.
  8. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
  9. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17.
  10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24.
  11. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7-17.
  12. SwissChems. BPC-157, 0.5 mg per capsule, 60-capsule product listing. Accessed 2026-07-01.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.